Staccato Prochlorperazine in Migraine (in Clinic)

Completed · Phase 2 · Has a placebo group

Conditions studied: Migraine Headache, With or Without Aura

In brief

Development of Staccato Prochlorperazine for the treatment of migraine headache.

Key facts

Study ID

NCT00610428

Run by

Alexza Pharmaceuticals, Inc.

People needed

75

Starts

2005-03-01

Expected to finish

2005-10-01

Last updated by the study team

2018-01-25

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Subjects who have migraine headache with or without aura (diagnosis according to International Headache Society guidelines) for at least 6 months, who have been pain free for at least 48 hours since the end of their last migraine attack, who have a pain rating of Moderate or Severe prior to dosing.

You may not qualify if…

• Subjects who have taken any other migraine or pain medication within 48 hours of randomization, with a history of allergy or intolerance to phenothiazines and related drugs, or are considered by the investigator, for any reason, to be an unsuitable candidate for receiving prochlorperazine, or unable to use the inhalation device, must be excluded.

Where it is running

• Arthur H. Elkind, MD — Mount Vernon, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.